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Abstract 
Introduction: The role of adjuvant chemotherapy in breast cancer is well established, as are its indications. Likewise, the role of 
neoadjuvant chemotherapy in locally advanced breast cancer is well established. The use of neoadjuvant chemotherapy in operable 
breast cancer has only recently become of interest to researchers. 
Patients and methods: This study included 34 cases of operable breast cancer that were given four cycles of neoadjuvant 
chemotherapy in the form of FEC100 then subjected to surgery. The surgery done was either breast conserving surgery or modified 
radical mastectomy. All patients completed the treatment regimen and no patients were excluded from the study. All surgical specimens 
were studied pathologically for chemotherapy effect. 
Results: An overall objective response was observed in 70.6% of the patients. Seven patients (20.6%) experienced a clinical complete 
response (cCR), 17 patients (50.0%) had partial response, nine patients (26.5%) had no change of their disease and only one patient 
had disease progression. Of the seven patients who had a cCR, only four patients (11.8%) had pathologic complete response (pCR), 
while pCR for the whole group was 14.7%( 5/34). Tumour size of more than 2 cm was observed in 28 patients (82.4%) at time of 
presentation, while tumour size of 2 cm or less was seen in six patients (17.6%) only. After completion of the course of chemotherapy, 23 
patients (67.6%) were observed to have tumours of 2 cm or less that allowed for less extensive resections. Twenty-three patients 
underwent breast conservative surgery (67.6%) while modified radical mastectomy was performed in 11 patients (32.4%). 
Conclusion: The use of neoadjuvant chemotherapy in operable breast cancer in this study was associated with tumour and axillary 
downstaging, which increased the proportion of cases undergoing breast conservation, with acceptable side effects and reasonable cost. 
During the limited follow-up time of this study no loco regional recurrences were recorded and one distant treatment failure was recorded. 
Its impact if any on overall or disease-free survival was not addressed in this study. Larger multi-centre randomized studies with a long 
follow-up are needed to compare the overall and disease-free survival benefit of this treatment modality, especially in different subtypes 
stratified by pathological response. 
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Trials that studied the role of adjuvant chemotherapy in the 
management of primary operable breast cancer conducted 
during the 1970s and 1980s showed significant improvements 
in progression-free and overall survival [1]. Conventionally, 
adjuvant systemic therapy is administered after local treatment 
in early breast cancer [2]. The role of neoadjuvant 
chemotherapy and endocrine therapy in locally advanced breast 
cancer has also become well established [3]. However, since 
the introduction of conservative treatment modalities, there has 
been considerable interest in the efficacy of preoperative 
chemotherapy to decrease tumour size. One of the potential 
benefits of preoperative chemotherapy is the more frequent 
usage of breast-conserving treatment modalities [4]. Moreover, 
it has been hypothesized that preoperative chemotherapy may 
have a more powerful effect on survival compared with post-
operative chemotherapy. It was found that animal models 
treated with chemotherapy or tamoxifen prior to surgical 
resection have improved survival, presumed as a result of a 
reduction in dissemination of cancer cells following surgery [5–
7]. Successful early treatment with systemic therapy is 
consistent with the Goldie-Coldman hypothesis, whereby 
metastases are being treated prior to the emergence of 
chemoresistant mutant clones [8]. 
Although the merits of preoperative chemotherapy in the 
treatment of locally advanced breast cancer are well 
established, the feasibility of preoperative chemotherapy in 
early breast cancer is still a matter of discussion. 
The European Organization for Research and Treatment of 
Cancer (EORTC) Breast Cancer Cooperative Group started a 
randomized trial in 1991 (EORTC trial 10902) to investigate the 
value of preoperative chemotherapy in early breast cancer and 
concluded that there is no difference in terms of overall survival 
or relapse-free survival between pre- and post-operative 
chemotherapy in early breast cancer. The data also concluded 
that, in such setting, preoperative chemotherapy allows better 
breast conservation. Survival data from the much larger NSABP 
B18 trial, with 1523 patients randomized to four cycles of 
adriamycin plus cyclophosphamide before or after surgery, have 
recently been reported with no significant differences in overall 
survival or relapse-free survival. 
The study presented here assesses the clinical as well as 
pathological response of breast cancer to a preoperative FEC-
100 regimen (fluorouracil 500 mg/m
2, epirubicin 100 mg/m
2, 
cyclophosphamide 500 mg/m
2 administered intravenously), and 
its significance in reducing the need for mastectomy and 
increasing the potential for more conservative breast surgery at 
the Menofia Oncology Hospital, Egypt. 
 
Patients and methods 
Patient characteristics 
Thirty-four women with breast cancer attending the Department 
of Surgical Oncology at the Menofia Oncology Hospital were 
enrolled into this study from June 2004 to November 2006. 
Patients had primary operable breast cancer (T1 to T3, N0 to 1 
and M0). Breast cancer was diagnosed by core-needle biopsy 
in all cases even if the patient had been previously diagnosed 
by fine-needle aspiration. A complete history was taken for all 
patients at the first presentation and a complete physical 
examination (including careful assessment of breast as well as 
axillary lymph nodes), routine laboratory tests, including CBC, 
liver and renal function tests, alkaline phosphatase, radiological 
tests, including a chest x-ray, pelvic-abdominal ultrasound, 
bilateral mammography with confirmatory breast ultrasound and 
complete echocardiography with assessment of the ejection 
fraction were carried out at this point and after the completion of 
the course of chemotherapy to assess treatment response. 
CBC was performed prior to each cycle of chemotherapy. 
Exclusion criteria consisted of the following: 
•  more than 70 years old; 
•  lumpectomy or axillary nodal biopsy; 
•  bilateral breast cancer; 
•  previous treatment for breast cancer; 
•  presence of distant metastases; 
•  pregnancy or lactation at the time of diagnosis; 
•  previous or current other malignancies; 
•  World Health Organization performance status more 
than 2; 
•  active cardiac disease (including EF below 55%); 
•  severe haematological, renal or hepatic abnormalities. 
All patients gave informed consent before entering the trial. 




















































Treatment consisted of four cycles of the FEC-100 regimen 
followed by surgery. Decision on the type of surgery (whether 
breast conserving surgery or mastectomy) was taken on the 
final assessment of the disease after the fourth cycle. 
The chemotherapy regimen consisted of four cycles of 
preoperative fluorouracil 500 mg/m
2, epirubicin 100 mg/m
2 and 
cyclophosphamide 500 mg/m
2 (FEC-100) administered 
intravenously, at three-week interval. Administration of FEC was 
delayed for a maximum of two weeks in the case of 
haematological, hepatic, renal or gastrointestinal toxicity. Dose 
modifications followed the guidelines stipulated by the EORTC 
Breast Cancer Cooperative Group [10]. 
Surgery was planned to be performed within 4–6 weeks of the 
fourth course of chemotherapy. 
Tumour response 
Clinical tumour size and nodal status were estimated before the 
start of chemotherapy as well as at the time of surgery by both 
palpation and mammography. The product of the two greatest 
perpendicular diameters was used to compare tumour size 
before and after chemotherapy, as defined by the International 
Union Against Cancer criteria [11]. A complete clinical response 
(cCR) was considered a complete disappearance of all clinically 
detectable malignant disease by palpation as well as 
mammography. The clinical response to chemotherapy was 
assessed before each cycle and at the time of surgery. If the 
tumour had become undetectable before completion of the four 
cycles of preoperative chemotherapy, chemotherapy was 
continued as outlined in the protocol. Clinical partial response 
was defined as 50% decrease in total tumour size after four 
cycles of chemotherapy at the time of surgery. An increase of 
25% in tumour size after a minimum of two courses of 
preoperative chemotherapy was considered to be progressive 
disease (PD). In patients with clinically negative nodes at 
presentation, the development of palpable nodes during the 
administration of chemotherapy was considered evidence of 
PD. After a diagnosis of PD, patients immediately underwent 
surgery before completing the preoperative chemotherapy 
schedule. If patients did not meet one of the above-mentioned 
criteria after four cycles of chemotherapy, they were classified 
as having stable disease. Tumour specimens were examined 
pathologically to assess the response and compare clinical to 
pathologic response. If no signs of residual malignant cells at 
the primary site and axillary lymph nodes were seen with 
histological examination, this was scored as a pathologic 
complete response (pCR). 
Pathology 
The surgical specimens were resected and oriented according 
to a defined surgical protocol described in the UK Guidelines 
[12]. For the therapeutic wide local excisions, once in the 
laboratory, the entire surface of the specimen was stained so 
that the margins of excision could be easily determined. The 
system followed to record the clinical response to neoadjuvant 
therapy was that of the International Union Against Cancer [11]. 
The histopathological response to neoadjuvant therapy was 
assessed according to criteria suggested by Smith et al [13]. 
These authors suggest that the features of the primary tumour 
should be scored from G1 to G5: 
1.  no reduction in overall numbers of tumour cells 
compared with pre-treatment core biopsy; 
2.  mild loss of tumour cells, but overall cellularity 
remaining high; 
3.  up to 90% reduction in tumour cells; 
4. marked disappearance with only small clusters 
remaining; 
5.  no invasive tumour, in situ carcinoma or stromal 
reaction remaining. 
Similarly, the lymph nodes are categorized as follows: 
A  true negative, no metastasis and no 
alterations; 
B  metastasis with no histological alterations; 
C  metastasis with alterations;  
D  no metastasis with alterations. 
For classification into these categories, it was essential that an 
invasive tumour was identified. This necessitated the detection 
of abnormal fibroelastic breast stroma that was devoid of normal 
lobular units and contained foamy macrophages, a moderate 
numbers of fibroblasts and other mononuclear inflammatory 
cells. Grade 5 response was deemed to represent a pCR of the 
primary cancer. 
Oestrogen and progesterone receptor status were ascertained 
in all specimens by immunohistochemical staining. In brief 5-
µm-thick sections of paraffin-embedded blocks were 
deparaffinized, dehydrated and then placed in citrate buffered


















Table 1: Patient characteristics at presentation   
saline (pH 6.0) and boiled for 20 minutes. Endogenous 
peroxidase activity was blocked by incubation with 6% H2O2 in 
methanol. The primary antibodies used were mouse monoclonal 
anti-human oestrogen receptor alpha, clone 1D5 (ready to use), 
mouse monoclonal anti-human progesterone receptor, clone 
PgR 636 (ready to use) and concentrated rabbit polyclonal anti-
human C-erb-B-2 oncoprotein (Her2/neu) (1:50), Hercept test, 
Code No. A0485 (Dako, Copenhagen, Denmark). The primary 
antibodies were incubated overnight. Immunoreactivity was 
visualized using Envision + (Dako cytomation, Glostrup, 
Denmark) with DAB chromogen as substrate and Mayer's 
haematoxylin as counterstain. Previous positive breast 
carcinoma for ER, PR and C-erb-B-2 were used as positive 
control for ER, PR and C-erb-B-2, respectively. Negative 
controls were prepared by substituting the primary antibodies 
with saline. 
Evaluation of immunostaining: nuclear staining was a 
prerequisite for assigning ER and PR positivity; both the number 
of tumour cell nuclei and the intensity of the reaction were 
evaluated. For C-erb-B-2, complete membranous staining in 
more than 10% was required for positivity. 
 
Results 
Thirty-four patients were enrolled in this study, patient 
characteristics are shown in Table 1. 
All patients received the planned chemotherapy in time except 
for two patients who had severe neutopenia requiring colony 
stimulating factors and treatment delay (one patient delayed for 
one week and the other for ten days). 


















Table 2: Chemotherapy toxicity profile for the 34 patients of the study
Chemotherapy was well tolerated with acceptable toxicities. 
Mild to moderate toxicity that is temporary and improves on 
simple and ordinary treatment is assigned as transient, while 
severe toxicity requiring specific aggressive treatment or 
admission is assigned as severe. Toxicity resulting from 
chemotherapy is shown in Table 2. 
Tumour size of more than 2 cm was observed in 28 patients 
(82.4%) at time of presentation, while only six patients (17.6%)


















Table 3: Surgery 
had a tumour size of 2 cm or less. After completion of the 
course of chemotherapy 23 patients (67.6%) had tumours of 2 
cm or less allowing less extensive resections. 
 
Surgery 
All patients underwent surgery within 35 days of the fourth cycle 
(average 19 days) in the form of conservative breast surgery in 
23 (67.6%) or modified radical mastectomy in 11 (32.4%) 
patients. 
Decision to perform breast conservative surgery (BCS) or 
modified radical mastectomy was based on the tumour size, 
breast tumour ratio and tumour position within the breast as 
shown in Table 3. Modified radical mastectomy was not 
followed by immediate reconstruction. Perioperative antibiotics 
were given to all patients and suction drains were used. Routine 
second day discharge from hospital with the drains was done 
for all patients. One lumpectomy patient was readmitted five 
days later for wider excision due to involved margins in the final 
report in spite of negative margins by frozen section. 



















Table 4: Clinical tumour response after chemotherapy 
 
Table 5: Pathologic tumour response after chemotherapy 
In patients undergoing BCS wide excision, staining of frozen 
sections was performed to control the margins. A problem was 
met in patients with cCR where no palpable tumour was 
present. In these patients, a quadrantectomy was done where 
the index quadrant of the tumour was excised. All cases 
undergoing BCS underwent full axillary dissection through a 
separate transverse lower axillary crease incision. 
Patients with a partial response lumpectomy was usually 
possible guided by the palpable lump although in three cases 
the breast mass was non-palpable and excision was performed 
after preoperative wire localization. Perioperative antibiotics 
were used for all patients, routine axillary suction drains were 
used while lumpectomy cavity drains were only used selectively. 
No mortalities were observed and only minor morbidity in the 
form of wound infection (two cases cleared spontaneously on 
treatment) and seroma (two cases in the mastectomy group 
required several aspirations and two cases of axillary seroma in 
the BCS group required aspiration and drain reinsertion in one 
case). The cosmetic results were evaluated as regard the 
appearance of the scars, the position and size of the areola-
nipple complex and the size of the breast in comparison with the 
other breast as very good (+++), moderate (++) or fair (+). 
In the BCS group, patient satisfaction with final cosmetic 
appearance was very satisfactory. The quadrantectomy patients 
were less satisfied with the final outcome than those undergoing 
lumpectomy. 
Tumour response 
An overall objective response was observed in 70.6% of the 
patients. Seven patients (20.6%) experienced a cCR, 17 
patients (50.0%) a partial response, nine patients (26.5%) had 
stable disease and one patient had disease progression (see 
Table 4). 
Pathologic complete response (pCR = grade 5) was seen in five 
(14.7%) patients and a pPR (grade 1–4) in 29 patients (Table 
5). There was no axillary lymph node involvement after 
chemotherapy in 26 patients (76.5%), of them true negative 
(category A) represented (58.8%) and signs of tumour 
regression (nodal fibrosis, mucin pools, aggregates of foamy 
histiocytes, myxoid or mucinous areas) were seen in five 
patients (category D). No response (category B) was observed 
in five patients (14.7%) and nodes with metastasis associated


















Table 6: Pathologic tumour response (graded) after chemotherapy 
 
pPR: pathologic partial response; pCR : pathologic complete response. 
with histological alterations were observed in three patients 
(8.8%). 
A tumour size of more than 2 cm was observed in 28 patients 
(82.4%) at the time of presentation, while a tumour size of 2 cm 
or less was seen in only five patients (17.6%). After completion 
of the course of chemotherapy, 23 patients (67.6%) were 
observed to have tumours of 2 cm or less so allowing for less 
extensive resections. Pathologic examination of axillary nodes 
revealed negative nodes in 26 patients and positive nodes in 
eight patients. Patients with positive nodes showed signs of 
regression while signs of complete tumour necrosis (burnt-out 
tumour) were seen in five patients with negative nodes. 
Further management 
Patients who had a good biological (pathological) response 
received two more cycles of the same regimen (FEC100) to a 
total of six cycles. Those who had a poor biological response 
were shifted to a taxane-containing regimen (docitaxel and 
cisplatin). All patients who underwent BCS received 
radiotherapy to the residual breast and chest wall as well as 
peripheral lymphatics (when indicated). Doses of radiotherapy 
to the residual breast and chest wall were 5000cGy in 25 
fractions over five weeks followed by a booster dose of 1500 to 
2000 cGy in 7–10 fractions over 10–15 days. Hormonal therapy 
was given to hormone responsive tumours. Follow-up of 
patients ranged from 6 to 28 months. No local recurrences were 
seen in any of our patients during this limited follow-up. One 
case developed distant metastasis (lung) 14 months after 
completion of therapy. 
 
Discussion 
Neoadjuvant and adjuvant chemotherapy for breast cancer 
have been compared in several previous clinical trials, but these 
trials did not definitively show that one approach was better than 
the other. The rationale for the use of neoadjuvant 
chemotherapy is: (1) the ability to reduce the extent of surgical 
procedures so, allowing for better cosmoses, (2) the ability to 
assess clinical as well as biological response of the given 
treatment, (3) eradication of micro-metastases, (4) to allow 
precise pathologic assessment of tumour response and (5) an 
opportunity for a scientific study of serial pre- and post-
treatment tumour biopsy samples [14]. 
The use of preoperative or primary chemotherapy was 
introduced approximately three decades ago in locally 
advanced breast cancer. Since then, its role in the management 
of locally advanced breast cancer has been firmly established. 
However, the advantages are not clear in early breast cancer 


















[15]. Despite the fact that preoperative chemotherapy may 
permit more breast-conserving treatment modalities, there may 
be problems, for instance in achieving adequate loco-regional 
control as a result of the difficulty of assessing tumour margins 
after the administration of preoperative chemotherapy [16]. 
Objective clinical response to neoadjuvant chemotherapy is 
reported to be between 65% and 91%. In our series, clinical 
response was seen in 70.6% of our cases, which is in 
accordance with other published reports [17,18]. Reported cCR 
rates are much lower ranging from 10% to 30% in most series, 
although some authors have reported a much lower rate. In our 
patients, cCR was seen in 20.6% of the cases, which is in 
accordance with most published reports [14]. Pathological 
complete responses are usually in the 9–15% range although 
there are some reports citing up to 30% pathological response 
rates. The reason for this discrepancy is usually because these 
authors include minimal disease (or only microscopic foci of 
disease) in their figures for cPR [19–21]. We were able to detect 
a cPR in 14.7% of our cases, which is also in agreement with 
most of the published data. 
Axillary downstaging is also reported to be a good prognostic 
factor. A primary tumour response is usually associated with a 
good axillary response. In our patients, 41.2% had palpable 
axillary nodes on presentation. After the end of chemotherapy, 
only 26.5% had palpable nodes. 
Although the benefits of preoperative chemotherapy in early 
breast cancer patients are less clear compared with the locally 
advanced breast cancer patients, the potential to enhance 
breast-conserving therapy makes it an attractive treatment 
modality. Several authors have firmly established the reduced 
need for mastectomy with neoadjuvant chemotherapy or 
neoadjuvant endocrine therapy [19,22,23]. In our experience, 
mastectomy was performed in only 32.4% of cases compared to 
a mastectomy rate of almost 80% observed at the Menofia 
University Cancer Center. This is in accordance with the finding 
of other authors who showed a significant reduction in the need 
for mastectomy; Schwartz et al [19] observed a 62% rate of 
breast conservation while Makaris et al reported an 89% rate of 
breast conservation with neoadjuvant chemotherapy compared 
to 78% when neoadjuvant chemotherapy was not used [19,23]. 
Complications after surgery were only minimal with no 
significant differences between patients who underwent a 
mastectomy and those who had BCS. The two major problems 
encountered by us were: (1) the difficulty in assessing margins 
by frozen section in patients who had been given neoadjuvant 
chemotherapy; and (2) the accurate localization of the tumour 
site in patients with cCR or cPR with minimal disease. Kuerer et 
al recommend radiological placement of metallic markers pre-
chemotherapy especially in women with tumours of less than 2 
cm to facilitate adequate resection and pathologic processing 
[24]. Kurbet et al also advocate intra-operative evaluation of the 
margins [25]. We agree with this and believe it will permit easier 
and more accurate surgery. Cosmetic results and patient 
satisfaction in our experience were acceptable, although those 
who had a lumpectomy had better results than those who 
underwent a quadrantectomy. 
Scholl et al and Mauriac et al both demonstrated in randomized 
trials a survival benefit for the neoadjuvant chemotherapy group 
[26,27]. Other studies, including the NSABP-18 and EORTC 
10902 trial, were unable to show any significant difference in 
overall survival, disease-free survival or loco-regional control. 
This is supported by most other authors, none of whom were 
able to demonstrate a survival benefit; however all the trials 
were able to demonstrate objective clinical response and 
decrease in the rate of mastectomy. Moreover, this was not 
associated with an increase in local recurrence. In the EORTC 
10902 trial, investigators compared preoperative versus post-
operative chemotherapy in breast cancer, where they found that 
the breast-conserving therapy rate was higher in the 
preoperative chemotherapy group in comparison with the post-
operative chemotherapy group. This finding, together with the 
equal loco-regional control rate in both groups, advocates the 
advantageous role of primary chemotherapy in breast-
conserving management [9,14,23]. 
In large trials, although there was no overall survival difference 
between neoadjuvant and adjuvant chemotherapy arms, a 
difference in overall survival, disease-free survival and loco-
regional control was observed in several subsets of patients. 
Survival was more significantly improved in the subset of 
patients who achieved pCR than in the other subsets of patient 
and than those receiving adjuvant chemotherapy. Likewise, 
survival was significantly better in patients who had an axillary 
pCR than in those who did not. Kuerer et al went further and 
stratified patients into three groups. They found the worst 
survival was for patients with gross axillary disease post-
chemotherapy, followed by those with occult micro-metastases, 
and the best survival was recorded for patients with pCR. These 
findings are supported by several other authors [28–30]. In our 
patients, the issues of survival and long-term loco-regional 
control were not addressed due to the low number of cases and 
the short follow-up period. 
The chemotherapy regimen used in our study was well tolerated 
and not associated with any major side effects necessitating 
discontinuation of the treatment. This is in accordance with most 


















other studies that reported the chemotherapy regimens were 
well tolerated with minimum morbidity [14,18]. 
In locally advanced and primary inoperable breast cancer, the 
purpose of preoperative treatment is to enable adequate local 
treatment. In patients with stage I or II breast cancer who are 
candidates for breast-conserving therapy irrespective of 
preoperative chemotherapy, the goal of preoperative 
chemotherapy is unclear. However, in stage I or II breast cancer 
patients who are not candidates for BCS, preoperative 
chemotherapy will definitely increase the proportion who may 
avoid a mastectomy. Some investigators argue that tumour 
response to preoperative chemotherapy is an independent 
predictor of treatment outcome. Therefore, it could be of benefit 
for breast cancer patients to adjust systemic adjuvant treatment 
at an early stage if tumour response to preoperative 
chemotherapy is inadequate. Controversially, preoperative 
chemotherapy might lead to over-treatment of breast cancer 
patients. This can be explained by the fact that patients receive 
systemic treatment regardless of histological staging of the 
tumour and axillary nodal status. 
Moreover, the possibility of studying the effects of 
chemotherapy on well-established tumour characteristics as 
well as experimental tumour markers makes chemotherapy in 
the preoperative setting highly attractive for research purposes 
[31]. The comparison of core needle biopsies with the same 
tumour after systemic treatment is a worthwhile reason to 
continue preoperative chemotherapy trials in early breast 
cancer. 
Unfortunately, not much data concerning quality-of-life issues in 
relation to preoperative chemotherapy are available in the 
literature. Quality-of-life studies, however, have been performed 
to investigate the effects of breast-conserving therapy versus 
mastectomy and show a less impaired body image for the 
conservative treatment modality [32]. Considering the fact that 
preoperative as well as post-operative chemotherapy seem to 
yield similar results in terms of prognosis, this might be a 
conclusive factor on the decision of which chemotherapeutic 
strategy should be chosen. Therefore, the role of preoperative 
chemotherapy should be studied in future trials that focus on 
research, equivalence, quality of life, and local control, in 
addition to better prognosis in patient subsets. 
 
Conclusion 
The use of neoadjuvant chemotherapy in operable breast 
cancer in this study was associated with tumour and axillary 
downstaging, which increased the proportion of cases 
undergoing breast conservation, with acceptable side effects 
and reasonable cost. The results from our study are in 
accordance with the most important studies looking at the same 
question. During the limited follow-up time of this study, no loco-
regional recurrences were recorded and one distant treatment 
failure was recorded. Its impact, if any, on overall or disease-
free survival was not addressed in this study. Larger multi-
centre randomized studies with a long follow-up are needed to 
compare the overall and disease-free survival benefit of this 
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